Jane S. Ricciuti, RPh, MS

Disclosures

November 12, 2003

In This Article

Introduction

In October, the US Food and Drug Administration (FDA) approved another agent as a counterterrorism measure, Radiogardase. Also approved was Namenda (memantine) as a novel treatment of moderate to severe dementia of the Alzheimer's type.

This month's column reviews FDA new product approvals and labeling changes for:

Alzheimer's disease

  • Namenda (memantine HCl) Tablets

Antidiabetic agents

  • Starlix (nateglinide) Tablets

Antidepressants

  • Paxil CR (paroxetine HCl) Tablets

Antiviral agents

  • Lexiva (fosamprenavir) Tablets

  • Rebetol (ribavirin) Capsules

Cardiovascular agents

  • Inspra (eplerenone) Tablets

Counterterrorism agents

  • Radiogardase (Insoluble Prussian Blue) Capsules

Estrogens

  • Estrasorb (estradiol) Topical Emulsion

Ophthalmic Agents

  • Elestat (epinastine HCI) Ophthalmic Solution

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....